Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Co-treatment Clear all
Completed Phase 4 Interventional Results available

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

NCT04772313
View directory record Official record
Conditions
Uncontrolled Gout
Interventions
Pegloticase, Methotrexate (MTX)
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

NCT04082962
View directory record Official record
Conditions
Exudative Retinal Detachment and Uveal Melanoma
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Ivana K. Kim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Not applicable Interventional

CONcussion Treatment After Combat Trauma (CONTACT)

NCT01387490
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Individualized Scheduled Telephone Support (ISTS), Usual Care (UC)
Behavioral · Other
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Durham, North Carolina • Fort Bragg, North Carolina • Fort Lewis, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 27, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional

Intervention for Communication Quality of Life in Primary Progressive Aphasia

NCT07219680
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Semantic Dementia, Logopenic Progressive Aphasia (LPA), Nonfluent Aphasia, Progressive, Progressive Aphasia, Semantic Variant Primary Progressive Aphasia (svPPA), Semantic Aphasia, Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA), Logopenic Progressive Aphasia, Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Nonfluent Progressive Aphasia
Interventions
Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia
Behavioral
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Remote Training in Rural Schools

NCT05034198
View directory record Official record
Conditions
Behavior Disorders
Interventions
Coping Power Program (CPP), Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS), Check-in/Check-out (CI/CO)
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 10:26 PM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT02519452
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 27, 2026, 10:26 PM EDT
Not yet recruiting Phase 4 Interventional

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With ADHD and Cannabis Use Disorder

NCT07838311
View directory record Official record
Conditions
ADHD, Cannabis Use Disorder
Interventions
Delayed-release, extended-release methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 26 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

NCT02124902
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, ASC42
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 27, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

NCT02861157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Planet T1D
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Not applicable Interventional

A Behavioral Therapy for Insomnia Co-existing With COPD

NCT01973647
View directory record Official record
Conditions
Insomnia, COPD, Chronic Obstructive Pulmonary Disease, Fatigue
Interventions
Cognitive Behavioral Therapy for Insomnia, COPD Education, Attention Control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Atorvastatin

NCT02749578
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

NCT00883935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2009 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

NCT00899470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

UARK 2003-33, Total Therapy III

NCT00081939
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 27, 2026, 10:26 PM EDT
Active, not recruiting Not applicable Interventional

Intervention to Enhance Coping and Help-seeking Among Youth in Foster Care

NCT06019377
View directory record Official record
Conditions
Adolescent Behavior, Psychosocial Functioning, Coping Behavior, Help-Seeking Behavior, Utilization, Health Care, Depression, Anxiety, Stress Disorders, Post-Traumatic, Emotion Regulation, Child Welfare
Interventions
Stronger Youth Networks and Coping (SYNC)
Behavioral
Lead sponsor
Portland State University
Other
Eligibility
16 Years to 20 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 27, 2026, 10:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities

NCT05558501
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Mild Intermittent Hypoxia, Sham MIH
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine and Prolonged Exposure in PTSD

NCT03960658
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
ketamine-enhanced prolonged exposure
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 27, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

NCT05085548
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Solid Tumor Malignancies
Interventions
ProAgio Dose Levels (DL) 1,2,3, ProAgio Dose Levels (DL) 4,5,6, ProAgio Dose Levels 4a,5a,6a
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 27, 2026, 10:26 PM EDT